Aakaar Medical Technologies Limited has reported a net profit of ₹663.76 lakh for the financial year ended March 31, 2026, an increase from ₹603.24 lakh in the previous year. Revenue from operations for FY26 stood at ₹6,696.41 lakh, compared to ₹6,158.28 lakh in FY25. The company's profit before tax rose to ₹919.18 lakh from ₹811.30 lakh in the prior year. The Board of Directors approved the audited financial results on May 15, 2026, subject to shareholder adoption at the ensuing Annual General Meeting.

Financial Performance

The total income for the year increased to ₹6,776.85 lakh from ₹6,176.00 lakh in FY25. Total expenses for FY26 were reported at ₹5,857.67 lakh, up from ₹5,364.70 lakh in the previous year. The basic and diluted earnings per share (EPS) for FY26 were 4.99, compared to 6.10 in FY25. The statutory auditors, M/s. C.B. Mehta & Associates Chartered Accountants, issued an audit report with an unmodified opinion on the financial results.

Operational Highlights

The company operates through two primary segments: Aesthetic Devices & Device Consumables and Aesthetic Products. The Aesthetic Products segment contributed the majority of revenue, generating ₹5,960.75 lakh for FY26, while the Aesthetic Devices & Device Consumables segment reported revenue of ₹735.66 lakh. The total number of doctors served expanded to 4,671 in FY26 from 4,403 in FY25.

Corporate Governance

Based on the recommendation of the Nomination and Remuneration Committee, the Board approved the re-appointment of Mr. Dilip Ramesh Meswani, Non-Independent Director, who is liable to retire by rotation. The re-appointment is subject to the approval of shareholders and the Securities and Exchange Board of India. Mr. Meswani is the Managing Director and a Promoter of the company.

Aakaar Medical Technologies Limited has approved the Aakar Medical Technologies Employee Stock Option Plan 2026, enabling the grant of 11,33,825 stock options to eligible employees, subject to shareholder approval. The Board of Directors also sanctioned an increase in the company's authorized share capital from ₹15 crore to ₹15.40 crore. These decisions were taken during a board meeting held on May 25, 2026, under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The ESOP 2026 is established in accordance with the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The options are available for grant to employees of the company and its subsidiaries in one or more tranches. These options are exercisable into not exceeding 11,33,825 fully paid-up equity shares, each with a face value of ₹10.

The exercise price per option will not be less than the face value of one equity share and will not exceed the fair market price as on the date of grant. The Board or the Nomination and Remuneration Committee retains the authority to determine the exact price within this range. The committee may also facilitate a cashless exercise of options for employees, subject to applicable laws.

Vesting for the options will commence after a minimum period of 12 months from the date of grant. The specific period within which the vested options may exercised will be determined by the Board or the Nomination and Remuneration Committee in accordance with the scheme's terms. Currently, no options have been vested, exercised, or lapsed, and no money has been realized from the exercise of options.

Concurrently, the Board approved an increase in the authorized share capital to accommodate the new issuance. The capital is being raised from ₹15,00,00,000 divided into 1,50,00,000 equity shares of ₹10 each, to ₹15,40,00,000 divided into 1,54,00,000 equity shares of ₹10 each. This change requires a consequent amendment to the capital clause of the Memorandum of Association and is subject to shareholder approval at the ensuing Annual General Meeting.

Key Details of Aakar Employee Stock Option Scheme-2026